suPAR recognized as one of the most important Danish discoveries

suPARnostic™ introduced at the XVI World AIDS Conference in Toronto 2006.

ViroGates Oversubscribes 3 Times Its Latest Private Round
In its largest financing round to date, ViroGates raises new capital from both current and new investors.

Foreign investors will get their first glimpse of ViroGates, as the small biotech company has been selected to present its business case to both UK and US investors in June.

ViroGates Completes Development of First-In-Class HIV Prognostic Kit
After years of extensive research and development, ViroGates has completed production of the first batch of suPARnostic™ kits for the monitoring of HIV disease progression.